Thienopyridines in percutaneous coronary interventions: standard procedures and high risk subsets.

Abstract

Due to the significant clinical and economic consequences of subacute stent thrombosis and the use of more complex devices (brachytherapy, drug eluting stents) in a variety of clinical situations (i.e. acute coronary syndromes), initiation and duration of a combined antiplatelet therapy using aspirin and a thienopyridine drug has become an issue of ongoing discussion in interventional cardiology. This review will provide a short introduction into the pathophysiology of stent thrombosis before standard procedures and critical issues on the use of thienopyridines in the setting of coronary interventions are discussed. Furthermore, clinically relevant issues that are not clearly covered by recommendations or guidelines like thienopyridines after coronary interventions in patients on chronic oral anticoagulation are also addressed.

• Authors: Peter W Radke, Rainer Hoffmann, Alma Zernecke, Axel Kaiser, Heribert Schunkert, Christian Weber
• Journal: Current pharmaceutical design (Curr Pharm Des) Vol. 12 Issue 10 Pg. 1281-6 ( 2006) ISSN: 1381-6128 [Print] United Arab Emirates
• PMID: 16611112 (Publication Type: Journal Article, Review)

Chemical References

• Biocompatible Materials
• Metals
• Platelet Aggregation Inhibitors
• Clopidogrel
• Ticlopidine

Topics

• Angioplasty, Balloon, Coronary
• Biocompatible Materials
• Brachytherapy
• Clopidogrel
• Coronary Artery Bypass
• Coronary Artery Disease (epidemiology, surgery)
• Humans
• Metals (adverse effects)
• Platelet Aggregation Inhibitors (economics, therapeutic use)
• Stents (adverse effects)
• Thrombosis (prevention & control)
• Ticlopidine (analogs & derivatives, economics, therapeutic use)